0000000000300089

AUTHOR

Lluís Puig

showing 2 related works from this author

Verrucous Plaque With Unusually Large Candida Blastoconidia: A Unique Clinicopathological Presentation of Systemic Mucocutaneous Candidiasis.

2018

Mucocutaneous candidiasis is a common infection affecting both immunocompetent and immunosuppressed individuals. Diversity in the clinical and histopathological presentation of mucocutaneous candidiasis is well known. However, the occurrence of cutaneous verrucous lesions and giant yeast-like structures has been rarely reported. In this article, we describe a case of disseminated mucocutaneous candidiasis in an immunosuppressed patient who presented as a verrucous plaque on the scrotum with giant Candida blastoconidia. This peculiar presentation expands the clinicopathological spectrum of mucocutaneous candidiasis and highlights the wide range of clinical manifestations and great morphologi…

0301 basic medicineMalemedicine.medical_specialtyAdolescent030106 microbiologychronic mucocutaneous candidiasisDermatologyMucocutaneous CandidiasisBlastoconidiumPathology and Forensic MedicinePrecursor Cell Lymphoblastic Leukemia Lymphoma030207 dermatology & venereal diseases03 medical and health sciencesImmunocompromised Host0302 clinical medicinegiant blastoconidiaScrotummedicineHumansCandidiasis chronic mucocutaneousCandidabusiness.industryCandidiasis Chronic MucocutaneousHematopoietic Stem Cell TransplantationVerrucous LesionGeneral Medicineatypical candidiasisPrecursor Cell Lymphoblastic Leukemia-LymphomaSpores FungalDermatologymedicine.anatomical_structurecandidaScrotumPresentation (obstetrics)businessThe American Journal of dermatopathology
researchProduct

Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars

2016

Abstract / Executive summary The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.

Executive summarybusiness.industryImmunologylcsh:RMedical practicelcsh:MedicineBiosimilarCell BiologyPharmacologyApplied Microbiology and BiotechnologyMicrobiologyRisk analysis (engineering)GeneticsMolecular MedicineMedicinebusinessMolecular BiologyEuropean Journal of Molecular and Clinical Medicine
researchProduct